Shield Therapeutics’ (STX) “Corporate” Rating Reaffirmed at FinnCap

FinnCap reissued their corporate rating on shares of Shield Therapeutics (LON:STX) in a research note published on Wednesday morning, ThisIsMoney.Co.Uk reports.

Other equities analysts have also issued research reports about the company. Peel Hunt reaffirmed a buy rating on shares of Shield Therapeutics in a research report on Tuesday. Peel Hunt reaffirmed a buy rating and issued a GBX 200 ($2.61) price target on shares of Shield Therapeutics in a research report on Wednesday, October 2nd.

Shield Therapeutics stock remained flat at $GBX 184.50 ($2.41) on Wednesday. The company’s stock had a trading volume of 22,472 shares, compared to its average volume of 48,665. The company has a debt-to-equity ratio of 0.26, a quick ratio of 4.57 and a current ratio of 4.79. The stock has a market capitalization of $216.21 million and a price-to-earnings ratio of 51.25. The firm has a 50-day moving average of GBX 182.95 and a two-hundred day moving average of GBX 131.22. Shield Therapeutics has a fifty-two week low of GBX 30 ($0.39) and a fifty-two week high of GBX 202 ($2.64).

About Shield Therapeutics

Shield Therapeutics plc, a specialty pharmaceutical company, in the development and commercialization of hospital-focused pharmaceuticals to treat unmet medical needs. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease.

Further Reading: How interest rates affect municipal bond prices

Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.